Article
Immunology
Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill, Antje Blumenthal, Nicholas A. Saunders
Summary: The study reveals that the SIRP alpha axis suppresses ADP responses to the anti-CD20 antibody by NLCs derived from CLL patients, and further demonstrates that this innate immune checkpoint contributes to resistance through the regulation of the Shp1-mediated pathway.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Chen Han, Cong Zhang, Hengxiao Wang, Lianmei Zhao
Summary: Exosomes play a crucial role in the communication between tumor cells and tumor-associated macrophages (TAMs), influencing tumor development. Targeting TAMs may hold promise as a therapeutic strategy in cancer treatment.
Article
Oncology
Jia Liu, Ze-Xian Liu, Jia-Jun Li, Zhao-Lei Zeng, Jin-Hong Wang, Xiao-Jing Luo, Chau-Wei Wong, Jia-Bo Zheng, Heng-Ying Pu, Hui Sheng, Qi-Nian Wu, Hao Li, Gang Wan, Bo Li, De-shen Wang, Rui-Hua Xu, Huai-Qiang Ju
Summary: Tumor-associated macrophages (TAM) are important for tumor development and progression. This study found that the long noncoding RNA MALR promoted aerobic glycolysis and angiogenesis in tumor cells by activating the HIF1a signaling pathway. It also identified the MALR-ILF3-HIF1a axis as a potential target for cancer therapy.
Article
Pharmacology & Pharmacy
Fahui Li, Congying Gao, Xueming Li, Jiangyun Wang, Yao Zhao, Yu Ke, Ying Liu, Hong-Min Liu, Zhenbo Hu, Liuya Wei, Zhe-Sheng Chen
Summary: The natural compound Jiyuan oridonin A (JOA) has been found to overcome the differentiation blockade in AML cells and leukemic stem-like cells, inhibiting their proliferation and offering a novel therapeutic strategy for AML.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Srijan Dubey, Sayak Ghosh, Debosmita Goswami, Debapriya Ghatak, Rudranil De
Summary: Macrophages are immune cells that can engulf and destroy target cells, including tumor cells. Some macrophages undergo a change to become polarized M2 macrophages while devouring cancer cells. M2 macrophages play important roles in metastasis, tumor suppression, and angiogenesis.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Lijuan Chong, Yao-Wen Jiang, Dongxu Wang, Pengzhao Chang, Kai Xu, Jingjing Li
Summary: In this study, biomimetic nanoparticles were developed to target M2-like tumor-associated macrophages and reprogram them for tumor immune suppression. In vitro and in vivo experiments demonstrated successful re-polarization of macrophages and inhibition of tumor growth.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Review
Immunology
Jiashu Han, Luochu Dong, Mengwei Wu, Fei Ma
Summary: Immunotherapy has revolutionized tumor treatment, but many patients still do not respond due to the immunosuppressive tumor microenvironment. Tumor-associated macrophages (TAMs) play a crucial role in shaping this microenvironment and interacting with intratumoral T cells. However, the heterogeneity and plasticity of TAMs make it challenging to target specific factors and develop effective therapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Chika Iwamoto, Kenoki Ohuchida, Tomohiko Shinkawa, Sho Okuda, Yoshiki Otsubo, Takashi Okumura, Akiko Sagara, Kazuhiro Koikawa, Yohei Ando, Koji Shindo, Naoki Ikenaga, Kohei Nakata, Taiki Moriyama, Yoshihiro Miyasaka, Takao Ohtsuka, Masatoshi Eto, Koichi Akashi, Masafumi Nakamura
Summary: This study found that in PDAC, macrophages derived from bone marrow can partially convert into CAF-like cells, acting as a specific subtype that promotes pancreatic cancer growth and invasion. This conversion may represent a novel therapeutic strategy.
Review
Oncology
Zijuan Zou, Hongfen Lin, Mengsen Li, Bo Lin
Summary: The chronic inflammation of tumor recruits TAMs to the TME and promotes polarization. Pro-inflammatory signals polarize macrophages to the M1 phenotype to enhance inflammation, while tumor inflammation changes the response to an anti-inflammatory response, altering macrophages from M1 to M2 to promote tumor progression. Hypoxia activates HIF in the TME, reprogramming macrophages to the M2 phenotype to support tumor development. Understanding the factors that drive phenotypic changes in TAMs in the inflammatory TME will aid in the development of cancer immunotherapy involving macrophages.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Zhengquan Wu, Ke Lei, Huaizhi Li, Jiali He, Enxian Shi
Summary: We established a prognostic model for melanoma related to M2-like tumor-associated macrophages and explored the role of VARS1 in melanoma progression and the development of immunotherapy resistance.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Immunology
Alexandra Neaga, Cristina Bagacean, Adrian Tempescul, Laura Jimbu, Oana Mesaros, Cristina Blag, Ciprian Tomuleasa, Corina Bocsan, Mihaela Gaman, Mihnea Zdrenghea
Summary: Research suggests that miRNAs play a role as tumor suppressors in favorably impacting AML outcomes, with macrophages increasingly being deciphered for their role in this process. miRNAs are not only proposed as diagnostic and prognostic biomarkers for AML, but are also seen as potential therapeutic approaches for various cancers, including AML.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Melanie A. Kimm, Christopher Klenk, Marianna Alunni-Fabbroni, Sophia Kaestle, Matthias Stechele, Jens Ricke, Michel Eisenblaetter, Moritz Wildgruber
Summary: This review provides an overview of the origin of tumor-associated macrophages, their polarization into different subtypes, and how characteristic markers of the subtypes can be used as targets for molecular imaging and theranostic approaches.
Review
Immunology
Jing Gao, Yuanzheng Liang, Liang Wang
Summary: This review focuses on the role of tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). It summarizes macrophage polarization, the effects on the TME, and emphasizes the importance of M2-like TAMs in immune checkpoint blockade and CAR-T cell therapy. It also discusses signaling pathways associated with TAM polarization and potential strategies for targeted therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Tessa Skroblyn, Jara J. Joedicke, Madlen Pfau, Kerstin Krueger, Jean-Pierre Bourquin, Shai Izraeli, Cornelia Eckert, Uta E. Hoepken
Summary: The study identified CXCL12-CXCR4 as the leading signaling axis for B-ALL cell migration and survival in the testicular leukemic niche. CXCR4 was found to be the only chemokine receptor robustly expressed on B-ALL cells in both diagnosis and relapse samples. Blocking CXCR4 functions showed promising results in preventing testicular infiltration and overall development of leukemia.
JOURNAL OF PATHOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ying Bai, Xin Zhang, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Chao Liang, Wenyang Wang, Yingru Xing, Jing Wu, Dong Hu
Summary: This study reveals that adenosine 2a receptor (A2aR) is specifically expressed on tumor cells from lung adenocarcinoma (LUAD) patients, closely related to prognosis and positively correlated with tumor-associated macrophages (TAMs) infiltration. Blocking A2aR inhibits TAMs migration and polarization, providing a potential therapeutic option for LUAD.
CHEMICO-BIOLOGICAL INTERACTIONS
(2023)
